Status:
RECRUITING
Intracardiac Flow Assessment in Cardiac Amyloidosis
Lead Sponsor:
Mayo Clinic
Conditions:
Amyloidosis Cardiac
Healthy Adults
Eligibility:
All Genders
40+ years
Brief Summary
The primary objective of this study is to define the intracardiac flow imaging biomarkers in cardiac amyloidosis.
Eligibility Criteria
Inclusion
- Subject is clinically stable without cardio-vascular-related hospitalizations within 6 weeks prior to enrollment as assessed by the investigators.
- Subject is able to provide written informed consent and is willing and able to complete study procedures.
- Currently in sinus rhythm by clinical assessment or documented electrocardiographic studies.
- Subject and disease characteristics noted by medical record review:
- Healthy control volunteers must also meet the following criteria: Karnofsky performance scale \> 80%; ECOG status 0 or 1.
- ATTR cardiac amyloidosis based on meeting all the following criteria: Diagnosis of amyloidosis within five years prior to study screening; Documentation of absence of AL, heavy chain disease, multiple myeloma or malignant lymphoproliferative disorders; Transthyretin amyloid deposits in cardiac tissue OR technetium (99mTc) pyrophosphate scintigraphy with grade 2 or 3 cardiac uptake OR Transthyretin amyloid deposits in non-cardiac tissue with echocardiographic evidence of cardiac involvement or an end-diastolic mean wall thickness \>12mm OR Transthyretin amyloid deposits in non-cardiac tissue with CMR diagnostic of amyloidosis
- AL with cardiac involvement based on meeting all the following criteria: Diagnosis of amyloidosis within five years prior to study screening; Histopathologic diagnosis of amyloidosis with AL protein identification; Documented clinical signs or symptoms consistent with heart failure; Cardiac involvement as defined by: Amyloid deposits in cardiac deposits OR Echocardiography with an end-diastolic mean wall thickness \> 12 mm in the absence of other causes OR Elevated NT-proBNP (\>332 ng/L) in the absence of renal failure or atrial fibrillation OR CMR diagnostic of amyloidosis;
- AL without cardiac involvement based on meeting all the following criteria: Diagnosis of amyloidosis within five years prior to study screening; Histopathologic diagnosis of amyloidosis with AL protein identification; No documented clinical signs and symptoms consistent with heart failure from AL; Absence of cardiac involvement as defined by: Echocardiography with an end-diastolic mean wall thickness \< 13 mm if the subject does not have other causes for increased wall thickness AND NT-proBNP \<333 ng/L if the subject does not have renal failure or atrial fibrillation AND No CMR diagnostic of amyloidosis if CMR is available prior to screening.
Exclusion
- Unable to consent or unable to complete all study procedures.
- Unable to ambulate for 6 minutes (confirmed at study coordinator visit).
- Unable to maintain in supine position for 30 minutes.
- Unable to maintain breath-holding for 10 seconds (confirmed at study coordinator visit).
- Contraindications for safe CMR scanning (e.g., uncontrolled claustrophobia, cochlear implant, implanted neural stimulator).
- Presence of implantable cardiac pacemaker or defibrillator.
- History of complex congenital heart disease, intracardiac shunt (except for patent foramen ovale), prosthetic valves, prosthesis in the main pulmonary artery or ascending thoracic aorta.
- Significant artifact from prior MRI studies.
- Pregnant or breast-feeding women.
- Weight equal to or greater than 155 kg.
- Maximum body side-to-side or anterior-posterior diameter equal to or greater than 70 cm.
- Documented non-sinus rhythm within 1 week prior to screening.
- For healthy controls, the following exclusion criteria apply, confirmed per chart review and/or patient report:
- History of cardiomyopathy or structural heart disease;
- History of valvular disease of greater than mild severity;
- History of coronary artery disease or coronary heart disease;
- History of cardiac or thoracic surgery.
- History of symptomatic, persistent atrial tachyarrhythmia, ventricular tachyarrhythmia, or bradyarrhythmia;
- Left ventricular hypertrophy or abnormally increased myocardial thickness by prior echocardiography, cardiac computed tomography, or CMR;
- Acute kidney injury, OR chronic renal disease with glomerular filtration rate \< 45 mL/min/1.73m\^2 as per medical record review.
- Uncontrolled hypertension of systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 90 mmHg as per medical record review;
- Taking three or more anti-hypertensive medications;
- Type 1 diabetes, OR uncontrolled type 2 diabetes mellitus of hemoglobin A1c greater than 8, as per medical record review;
- Taking three or more diabetic medications;
- History of confirmed stroke or transient ischemic attack, as per medical record review;
- Current cigarette smoker;
- History of plasma cell dyscrasia or chronic malignant hematologic diagnosis;
- BMI \> 35 kg/m\^2.
Key Trial Info
Start Date :
July 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05379101
Start Date
July 20 2022
End Date
June 1 2026
Last Update
July 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905